GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » Other Long Term Assets

OKYO Pharma (OKYO Pharma) Other Long Term Assets : $-0.00 Mil (As of Mar. 2023)


View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma Other Long Term Assets?

OKYO Pharma's other long-term assets for the quarter that ended in Mar. 2023 was $-0.00 Mil.

OKYO Pharma's quarterly other long-term assets declined from Mar. 2022 ($0.00 Mil) to Sep. 2022 ($-0.00 Mil) but then increased from Sep. 2022 ($-0.00 Mil) to Mar. 2023 ($-0.00 Mil).

OKYO Pharma's annual other long-term assets increased from Mar. 2021 ($-0.00 Mil) to Mar. 2022 ($0.00 Mil) but then declined from Mar. 2022 ($0.00 Mil) to Mar. 2023 ($-0.00 Mil).


OKYO Pharma Other Long Term Assets Historical Data

The historical data trend for OKYO Pharma's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OKYO Pharma Other Long Term Assets Chart

OKYO Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OKYO Pharma Semi-Annual Data
Sep13 Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

OKYO Pharma Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.


OKYO Pharma (OKYO Pharma) Business Description

Traded in Other Exchanges
Address
14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
Executives
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob director, officer: Chief Executive Officer
Gabriele M Cerrone director, 10 percent owner, officer: Executive Chairman 265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer director C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon director PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah officer: Chief Financial Officer 55 PARK LANE, LONDON X0 W1K 1NA